Otros idiomas Veracyte, Inc.

Acciones

VCYT

US92337F1075

Tiempo real estimado Cboe BZX Otros sitios de cotización 15:47:14 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
20 ^USD	+2,17 %		-1,66 %	-28,86 %

15/04	VERACYTE, INC. : Obtiene una recomendación de compra de Goldman Sachs	ZM
26/02	VERACYTE, INC. : Morgan Stanley mantiene una recomendación de venta	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression among Patients Undergoing Active Surveillance	23/04
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024	22/04
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance	22/04
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024	16/04
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines	27/02
Sector Update: Health Care Stocks Mixed Premarket Friday	23/02
Veracyte's Q4 Loss Widens, Revenue Increases; Issues 2024 Revenue Outlook; Shares Down Pre-Bell	23/02
Veracyte: Q4 Earnings Snapshot	22/02
Earnings Flash (VCYT) VERACYTE Reports Q4 Revenue $98.2M, vs. Street Est of $92.8M	22/02
Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024	22/02
Veracyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results	22/02
Veracyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference	21/02
Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors	13/02
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024	08/02
Veracyte Closes $70 Million C2i Genomics Acquisition	06/02
Veracyte Completes Acquisition of C2i Genomics	06/02
Veracyte, Inc. completed the acquisition of C2i Genomics, Inc.	05/02
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform	08/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Veracyte, Inc.

Acciones

VCYT

US92337F1075

Otros idiomas

Filtros